Ubs Asset Management Americas Inc Esperion Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

  • $477 Billion
  • Q2 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 249,500 shares of ESPR stock, worth $763,470. This represents 0.0% of its overall portfolio holdings.

Number of Shares
249,500
Holding current value
$763,470
% of portfolio
0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
BUY
$0.73 - $1.41 $182,135 - $351,795
249,500 New
249,500 $244,000
Q1 2023

May 15, 2023
BUY
$1.46 - $7.3 $58,089 - $290,445
39,787 Added 55.49%
111,482 $177,000
Q4 2022

Feb 14, 2023
BUY
$5.09 - $8.5 $364,927 - $609,407
71,695 New
71,695 $446,000
Q2 2021

Aug 16, 2021
BUY
$19.4 - $28.71 $121,055 - $179,150
6,240 Added 22.91%
33,476 $708,000
Q1 2021

May 14, 2021
BUY
$25.12 - $36.89 $106,383 - $156,229
4,235 Added 18.41%
27,236 $763,000
Q3 2020

Nov 13, 2020
SELL
$31.18 - $52.71 $6,454 - $10,910
-207 Reduced 0.89%
23,001 $854,000
Q2 2020

Aug 14, 2020
BUY
$30.04 - $51.31 $117,276 - $200,314
3,904 Added 20.22%
23,208 $1.19 Million
Q1 2020

May 15, 2020
SELL
$27.44 - $73.84 $51,203 - $137,785
-1,866 Reduced 8.81%
19,304 $608,000
Q4 2019

Feb 14, 2020
BUY
$35.4 - $59.82 $3,115 - $5,264
88 Added 0.42%
21,170 $1.26 Million
Q3 2019

Nov 14, 2019
BUY
$34.47 - $47.53 $123,885 - $170,822
3,594 Added 20.55%
21,082 $772,000
Q2 2019

Aug 15, 2019
BUY
$40.1 - $52.33 $100,169 - $130,720
2,498 Added 16.66%
17,488 $0
Q1 2019

May 14, 2019
BUY
$40.11 - $53.57 $44,000 - $58,766
1,097 Added 7.9%
14,990 $0
Q4 2018

Feb 13, 2019
BUY
$36.99 - $59.11 $166,196 - $265,581
4,493 Added 47.8%
13,893 $639,000
Q3 2018

Nov 14, 2018
BUY
$40.74 - $51.41 $134,442 - $169,653
3,300 Added 54.1%
9,400 $0
Q2 2018

Aug 14, 2018
SELL
$36.2 - $76.4 $2.2 Million - $4.64 Million
-60,674 Reduced 90.86%
6,100 $0
Q1 2018

May 14, 2018
BUY
$65.94 - $80.76 $97,591 - $119,524
1,480 Added 2.27%
66,774 $0
Q4 2017

Feb 09, 2018
BUY
$43.47 - $67.43 $1.1 Million - $1.71 Million
25,396 Added 63.65%
65,294 $0
Q3 2017

Nov 13, 2017
BUY
$43.8 - $52.77 $1.75 Million - $2.11 Million
39,898
39,898 $0

Others Institutions Holding ESPR

# of Institutions
183
Shares Held
106M
Call Options Held
139K
Put Options Held
604K
View Full List

About Esperion Therapeutics, Inc.

ESPR Quotes by TradingView
  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $204M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email